Click on the panels below to find out more about our latest hosted content
This resource contains two CPD accredited modules to increase your knowledge of alcohol misuse and Wernicke’s Encephalopathy.For PI click hereJOB CODE:UKIRE/PAB/0111AUGUST 2018This information is intended for UK and IRE healthcare professionals only.
An award winning1 design containing the effective combination of drugs you know.
Learn how Integrated Health Solutions, the services and solutions division of Medtronic, partners with healthcare providers to optimise cost and outcomes.
Using the NICE guidelines to manage frequent infant regurgitation with marked distress Based on NICE guidelines [NG1], January 2015¹
A survey of 710 people with rosacea and 554 doctors has revealed valuable insights on the invisible impact of a visible disease for the patients and the community. It is time to fight back against stereotypes and talk openly about rosacea burden.
Find out more about how we can reduce the burden of eczema for patients, GPs and the NHS
Find out more about the latest Pfizer Anti-Infectives offerings
PP-ZVA-GBR-0479
August 2018
Information intended for UK healthcare professionals only
The path of Idiopathic Pulmonary Fibrosis (IPF) can be unpredictable.Time is critical in IPF.Visit the microsite to:
This resource is intended for UK healthcare professionals only and provides information on the management of patients with inflammatory bowel disease or listed for surgery.• How to meet the full iron need of inflammatory bowel disease patients with iron deficiency anaemia.• Meeting the challenges of perioperative anaemia.Job code: UK-MONF-0918-00023Date of preparation: September 2018
The more targetable genes are identified and treatment choice grows, the more clinical practice is shifting towards an era of precision medicine. Being aware of this, Roche is collaborating with molecular insights leader Foundation Medicine
This resource provides information on the management of patients with adult ADHD.Job code: C-APROM/UK//2853Date of prep: May 2019Initiated and funded by Takeda Pharmaceuticals Limited.